Common Side Effects of Zavicefta (Ceftazidime-Avibactam) Combined with Aztreonam
The most common side effects of ceftazidime-avibactam plus aztreonam combination therapy include transaminase elevations (particularly with higher aztreonam doses), diarrhea, nausea/vomiting, rash, and local injection site reactions, with the overall safety profile being generally well-tolerated in clinical practice.
Individual Drug Side Effects
Aztreonam Side Effects (from FDA Label)
The FDA-approved aztreonam label 1 documents the following adverse reactions:
Most Common (≥1% incidence):
- Local reactions: Phlebitis/thrombophlebitis (1.9% IV), injection site discomfort/swelling (2.4% IM)
- Gastrointestinal: Diarrhea, nausea/vomiting (1-1.3%)
- Dermatologic: Rash (1-1.3%)
Less Common (<1% incidence):
- Hematologic: Neutropenia, thrombocytopenia, anemia, eosinophilia
- Hepatic: Hepatitis, jaundice, elevated transaminases
- Renal: Increased serum creatinine
- Neurologic: Seizure, confusion, encephalopathy, dizziness, paresthesia
- Hypersensitivity: Anaphylaxis, angioedema, bronchospasm (rare)
- Other: C. difficile-associated diarrhea, fever, headache
Ceftazidime-Avibactam Side Effects
While specific FDA label data for ceftazidime-avibactam wasn't provided in the evidence, real-world data from 203 patients 2 showed:
- Acute kidney injury: 10 patients (4.9%)
- C. difficile infection: 3 patients (1.5%)
- Rash: 2 patients (1.0%)
- Gastrointestinal intolerance: 1 patient (0.5%)
- Neutropenia: 1 patient (0.5%)
Combination-Specific Concerns
Transaminase Elevations - Critical Consideration
The most important combination-specific side effect is asymptomatic transaminase elevation, which occurs in approximately 40% of patients receiving ceftazidime-avibactam plus aztreonam 3. This finding comes from a healthy volunteer study and is dose-dependent on aztreonam:
- High-risk dosing: Aztreonam 8 g/day (either continuous infusion or every 6 hours) - highest elevation rates
- Lower-risk dosing: Aztreonam 6 g/day - approximately 6% elevation rate in clinical trials 3
- Key point: Elevations were asymptomatic and resolved with drug cessation
- Important: The transaminitis was attributed to aztreonam dosing, not the co-administration with ceftazidime-avibactam
Nephrotoxicity Risk
Nephrotoxicity remains low with this combination 4. Monte Carlo simulation modeling across varying renal function demonstrated that neurotoxicity risk (defined as ceftazidime Cmin >80 mg/L) remained low across all renal strata when appropriate dose adjustments were made 4.
Pediatric Population
In pediatric patients receiving aztreonam 1:
- Rash: 4.3%
- Diarrhea: 1.4%
- Fever: 1.0%
- Local reactions (IV): Pain (12%), erythema (2.9%), phlebitis (2.1%)
- Neutropenia: 11.3% in children <2 years receiving 30 mg/kg every 6 hours
- Transaminase elevations: 15-20% in children ≥2 years receiving 50 mg/kg every 6 hours
A recent case series in preterm infants 5 reported reversible adverse effects including liver function abnormalities, increased serum creatinine, hypomagnesemia, and thrombocytopenia, though one patient experienced status epilepticus (causality uncertain).
Clinical Monitoring Recommendations
Based on the evidence, monitor for:
- Liver function tests - particularly when using aztreonam ≥6 g/day; check baseline and weekly
- Renal function - baseline and every 2-3 days, especially in critically ill patients
- Complete blood count - monitor for neutropenia, thrombocytopenia
- Electrolytes - particularly magnesium levels
- Signs of C. difficile infection - diarrhea during or after treatment
- Neurologic status - particularly in patients with renal impairment or CNS infections
Important Caveats
- The incidence of adverse events is low overall 6, with guidelines noting that "the benefit of ceftazidime-avibactam combined with aztreonam probably outweighs potential harm"
- Most adverse effects are reversible with dose adjustment or discontinuation
- Combination therapy did not increase adverse events compared to monotherapy in retrospective cohorts 7
- Avoid in patients with documented β-lactam hypersensitivity
- Use cautiously in patients with seizure disorders or significant renal impairment without appropriate dose adjustment